Elsevier

Neurobiology of Disease

Volume 23, Issue 3, September 2006, Pages 679-688
Neurobiology of Disease

The α2C-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder

https://doi.org/10.1016/j.nbd.2006.05.007Get rights and content

Abstract

Drugs that modify noradrenergic transmission such as atomoxetine and clonidine are increasingly prescribed for the treatment of attention deficit hyperactivity disorder (ADHD). However, the therapeutic targets of these compounds are unknown. Norepinephrine is also implicated in the hyperactivity exhibited by coloboma mice. To identify the receptor subtypes that regulate the hyperactivity, coloboma mice were systematically challenged with adrenergic drugs. The β-adrenergic receptor antagonist propranolol and the α1-adrenergic receptor antagonist prazosin each had little effect on the hyperactivity. Conversely, the α2-adrenergic receptor antagonist yohimbine reduced the activity of coloboma mice but not control mice. Subtype-selective blockade of α2C-, but not α2A- or α2B-adrenergic receptors, ameliorated hyperactivity of coloboma mice without affecting activity of control mice, suggesting that α2C-adrenergic receptors mediate the hyperactivity. Localized in the basal ganglia, α2C-adrenergic receptors are in a prime position to impact locomotor activity and are, therefore, potential targets of pharmacotherapy for ADHD.

Introduction

Attention deficit hyperactivity disorder (ADHD) is characterized by hyperactivity, inattention, and impulsivity and is a common pediatric neuropsychiatric disorder (Olfson, 1992, Faraone et al., 2003, CDC, 2005). The stimulants amphetamine and methylphenidate, which are indirect agonists that increase extracellular monoamine concentrations by inhibiting reuptake and/or promoting release, are the primary treatments for ADHD (Robison et al., 1999). Amphetamine benefits some patients, methylphenidate benefits others, and still others respond to both or neither medication (Winsberg et al., 1974, Arnold et al., 1978). It is not understood how stimulants ameliorate symptoms of some patients or why subpopulations of patients respond differently to stimulants. A better understanding of the mechanisms underlying ADHD would resolve these questions.

The efficacy of stimulants suggests that dopaminergic and/or noradrenergic dysregulation contribute to the expression of ADHD. In support of this assertion, genetic association studies implicate molecules that regulate both dopaminergic and noradrenergic neurotransmission, including receptors and transporters (Cook et al., 1995, Comings et al., 1996, Comings et al., 1999, Comings et al., 2000, Daly et al., 1999, Faraone et al., 2001, Holmes et al., 2002, Maher et al., 2002, Grady et al., 2003, Roman et al., 2003, Kustanovich et al., 2004). Further, in several different studies assessing catecholamine utilization, both the dopamine metabolite homovanillic acid (HVA) and the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) are correlated with the behavioral signs of ADHD in children. For example, ADHD patients display a positive correlation between severity of hyperactivity and HVA concentration in cerebrospinal fluid (Castellanos et al., 1994, Castellanos et al., 1996), and between scores on the Test of Variables of Attention (a standardized reaction time test that measures sustained attention and impulsivity) and norepinephrine metabolites in urine (Llorente et al., 2006). Diversity in psychostimulant response, genetic polymorphisms, and neurochemical abnormalities suggests that ADHD is not attributable to any single pathophysiologic mechanism. Consequently, it is unlikely that a universal treatment will ameliorate symptoms of all ADHD patients. In the absence of specific therapeutic targets, the treatment strategy progresses from stimulants to nonstimulant drugs that increase synaptic norepinephrine (reuptake inhibitors), to drugs that are thought to decrease noradrenergic transmission (clonidine, guanfacine, or propranolol—alone or in combination with stimulants) (Silver, 1999, Pliszka, 2003).

Coloboma mice may be a useful tool for developing rational therapeutic strategies for ADHD. These mice exhibit spontaneous hyperactivity caused by a semidominant deletion mutation that includes the Snap25 gene. This mutation results in a 50% reduction in the expression of the protein SNAP-25 (Hess et al., 1992). SNAP-25 concentrates in presynaptic terminals and is expressed in neurons throughout the brain, with the highest levels of expression found in the neocortex, hippocampus, anterior thalamic nuclei, substantia nigra, and cerebellar granule cells (Oyler et al., 1989). SNAP-25 is associated with the plasma membrane of axon terminals and has been identified as a component of the machinery essential for docking synaptic vesicles at the presynaptic membrane in readiness for Ca2+-triggered neurotransmitter exocytosis (Sollner et al., 1993a, Sollner et al., 1993b). Important for this work, several independent research groups identify an association between the SNAP25 gene and ADHD in humans (Barr et al., 2000, Brophy et al., 2002, Mill et al., 2002, Kustanovich et al., 2003). Also similar to ADHD patients, amphetamine ameliorates hyperactivity of coloboma mice (Hess et al., 1996), suggesting a relationship between abnormal catecholamine regulation and hyperactivity in these mice. Indeed, brain norepinephrine concentrations are increased in coloboma mice compared to control littermates, and depletion of norepinephrine ameliorates hyperactivity of coloboma mice (Jones et al., 2001, Jones and Hess, 2003), suggesting that dysregulation of norepinephrine contributes to the coloboma mouse phenotype. To determine the adrenergic receptor subtypes that regulate locomotor hyperactivity in coloboma mice, we systematically tested the effects of noradrenergic compounds on locomotor activity of coloboma mice, beginning with nonselective drugs and progressing to increasingly selective compounds.

Section snippets

Mice

Coloboma (Cm/+) mice and control (+/+) C3H/HeSnJ mice (Jackson Laboratories, Bar Harbor, Maine) were bred and housed in group cages (2–4 mice/cage) with corncob bedding at Johns Hopkins University vivarium (lights on at 7 a.m. and off at 9 p.m.). Mutants and controls were age- and sex-matched male and female mice; most mutant and control pairs were littermates. Water and standard laboratory rodent food (2018SX; Harlan Teklad, Madison, WI) were available ad libitum throughout all experiments.

Results

Consistent with previous results (Hess et al., 1992), coloboma mice were significantly more active than control littermates (Fig. 1A; Student's t test, t(62) = 8.70, P < 0.0001). In addition to overt hyperactivity, coloboma mice also exhibit head bobbing, which may substantively contribute to total beam breaks. Therefore, a more detailed analysis was performed to distinguish fine movements–defined as repetitive breaks of a single beam, which would include behaviors such as head bobbing–from

Discussion

The major obstacle to successfully treating ADHD without the use of stimulants is that the most beneficial noradrenergic targets of pharmacotherapy are unknown. Here we used coloboma mice to isolate potential targets. The results presented here suggest that β-adrenergic receptors do not regulate the locomotor hyperactivity of coloboma mice. Instead, our systematic investigation of the locomotor response of coloboma mice to adrenergic drugs implicated α2-adrenergic receptors–specifically, α2C

Acknowledgments

Supported by United States Public Health Service Grant R01 NS34845 (EJH) and Kirshstein-National Research Service Award Individual Fellowship F31 NS42489 (KJB).

References (63)

  • M. Holmberg et al.

    Regional distribution of alpha(2C)-adrenoceptors in brain and spinal cord of control mice and transgenic mice overexpressing the alpha(2C)-subtype: an autoradiographic study with [(3)H]RX821002 and [(3)H]rauwolscine

    Neuroscience

    (2003)
  • M.D. Jones et al.

    Norepinephrine regulates locomotor hyperactivity in the mouse mutant coloboma

    Pharmacol. Biochem. Behav.

    (2003)
  • M.D. Jones et al.

    Abnormal presynaptic catecholamine regulation in a hyperactive SNAP-25-deficient mouse mutant

    Pharmacol. Biochem. Behav.

    (2001)
  • D. Michelson et al.

    Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

    Biol. Psychiatry

    (2003)
  • J. Sallinen et al.

    d-Amphetamine and l-5-hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the alpha2C-adrenergic receptor subtype

    Neuroscience

    (1998)
  • M. Scheinin et al.

    Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain

    Brain Res. Mol. Brain Res.

    (1994)
  • L.B. Silver

    Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children

    Pediatr. Clin. North Am.

    (1999)
  • T. Sollner et al.

    A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion

    Cell

    (1993)
  • S. Uhlen et al.

    Autoradiographic studies of central alpha 2A- and alpha 2C-adrenoceptors in the rat using [3H]MK912 and subtype-selective drugs

    Brain Res.

    (1997)
  • R. Wang et al.

    Expression of alpha 2-adrenergic receptor subtypes in the mouse brain: evaluation of spatial and temporal information imparted by 3 kb of 5′ regulatory sequence for the alpha 2A AR-receptor gene in transgenic animals

    Neuroscience

    (1996)
  • P. Young et al.

    Novel alpha 2-adrenoceptor antagonists show selectivity for alpha 2A- and alpha 2B-adrenoceptor subtypes

    Eur. J. Pharmacol.

    (1989)
  • D.W. Zeng et al.

    Distribution of alpha 2-adrenergic receptor mRNAs in the rat CNS

    Brain Res. Mol. Brain Res.

    (1991)
  • W. Zhang et al.

    The alpha2C-adrenoceptor modulates GABA release in mouse striatum

    Brain Res. Mol. Brain Res.

    (2003)
  • L.E. Arnold et al.

    Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis

    Arch. Gen. Psychiatry

    (1978)
  • C.L. Barr et al.

    Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder

    Mol. Psychiatry

    (2000)
  • K. Brophy et al.

    Synaptosomal-associated protein 25 (SNAP-25) and attention deficit hyperactivity disorder (ADHD): evidence of linkage and association in the Irish population

    Mol. Psychiatry

    (2002)
  • F.X. Castellanos et al.

    Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder

    Neuropsychopharmacology

    (1996)
  • C.f.D.C.a.P. CDC

    Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder—United States, 2003

    MMWR Morb. Mortal. Wkly. Rep.

    (2005)
  • D.E. Comings et al.

    Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes—DRD2, D beta H, and DAT1

    Am. J. Med. Genet.

    (1996)
  • D.E. Comings et al.

    Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects

    Clin. Genet.

    (1999)
  • D.E. Comings et al.

    Comparison of the role of dopamine, serotonin, and noradrenaline genes in ADHD, ODD and conduct disorder: multivariate regression analysis of 20 genes

    Clin. Genet.

    (2000)
  • Cited by (22)

    • Review of rodent models of attention deficit hyperactivity disorder

      2022, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      Striatal DRD1 and DRD2 expression are unaltered. TH expression is unaltered in VTA and substantia nigra of these mice, whereas TH and alpha 2A adrenoreceptor expression are increased in the locus coeruleus (Bruno and Hess, 2006). There are also changes in norepinephrine.

    • Function of brain α<inf>2B</inf>-adrenergic receptor characterized with subtype-selective α<inf>2B</inf> antagonist and KO mice

      2016, Neuroscience
      Citation Excerpt :

      Findings with mice overexpressing the α2C receptor further support these KO findings and strongly suggest that the α2C receptor is involved in inhibiting sensory information processing (Sallinen et al., 1998, 1999; Scheinin et al., 2001). In addition, support for a role for α2C receptors in locomotion is suggested by the effects of α2C-antagonist-mediated inhibition of hyperactivity in the coloboma mice (Bruno and Hess, 2006). Previous α2B KO studies suggest α2B receptor involvement in salt-induced hypertension, and a loss of α2B results in disrupted placental vasculature during prenatal development (Brede et al., 2004).

    • Role for monoaminergic systems in the antidepressant-like effect of ethanol extracts from Hemerocallis citrina

      2012, Journal of Ethnopharmacology
      Citation Excerpt :

      To explore the detailed neurochemical mechanisms involved in the antidepressant-like effect of HCE, mice receiving drugs for two weeks were used for determinations of 5-HT, NA and DA levels in the brain regions of frontal cortex and hippocampus after TST. The doses of the drugs used were selected on the basis of the literature data which were previously reported not to increase the locomotor activity (Kittner et al., 2000; O’Neill and Conway, 2001; Wellman et al., 2002; Zomkowski et al., 2004; Bruno and Hess, 2006; Benturquia et al., 2008; Mueller et al., 2009). The OFT was also carried out to rule out any psychostimulant effect of the interaction of WAY 100635, cyproheptadine, prazosin, yohimbine, propranolol, SCH23390, sulpiride and HCE.

    View all citing articles on Scopus
    View full text